1	Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms
2	
3	Juan Manuel Carreño ¹ , Damodara Rao Mendu ² , Viviana Simon ^{1,4,5} , Masood A Shariff ³ , Gagandeep
4	Singh ¹ , Vidya Menon ^{3*} , Florian Krammer ^{1*}
5	
6	¹ Dept. of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
7	² Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount
8	Sinai, New York, USA
9	³ Department of Internal Medicine, NYC Health + Hospitals/Lincoln, The Bronx, NY, USA.
10	⁴ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai,
11	New York, NY.
12	5 The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New
13	York, NY
14	
15	*To whom correspondence should be addressed: <u>menonv@nychhc.org</u> and
16	<u>florian.krammer@mssm.edu</u>
17	
18	

19 Abstract

20 Serological tests are important tools helping to determine previous infection with severe acute 21 respiratory disease coronavirus 2 (SARS-CoV-2) and to monitor immune responses. The current 22 tests are based on spike (S), the receptor binding domain (RBD), or the nucleoprotein (NP) as substrate. Here, we used samples from a high seroprevalence cohort of health care workers (HCWs) 23 24 to perform a longitudinal analysis of the antibody responses using three distinct serological assays. 25 501 serum samples were tested using: a) a research-grade RBD and spike based tandem enzymelinked immunosorbent assav (MS-RBD ELISA, MS-spike ELISA), b) a commercial RBD and spike 26 27 based tandem ELISA (Kantaro-RBD, -spike), and c) a commercial NP-based chemiluminescent 28 microparticle immunoassay (CMIA, Abbott Architect). Seroprevalence ranged around 28% during 29 the early stage of the pandemic (a: 28.4% positives; b: 28.1%; c: 27.3%). Good correlation was 30 observed between the MS and Kantaro RBD ELISAs and between the MS and Kantaro spike ELISAs. Bv contrast. modest correlations were observed between the Abbott Architect and both RBD and 31 32 spike-based assays. A proportion of HCWs (n=178) were sampled again 3-5 months after the first 33 time point. Although antibody levels declined in most of the positive individuals, the overall seroprevalence measured by RBD-spike based assays remained unchanged. However the 34 35 seroprevalence of NP-reactive antibodies significantly declined. Lastly, we tested six samples of 36 individuals who received two doses of SARS-CoV-2 mRNA vaccine and found that seroconversion 37 was detected by the RBD-spike assays but - of course as expected - not the NP based assay. In 38 summary, our results consolidate the strength of different serological assays to assess the 39 magnitude and duration of antibodies to SARS-CoV-2.

40

41

43 Introduction

44 In the advent of the current pandemic caused by the severe acute respiratory syndrome coronavirus 45 2 (SARS-CoV-2), pandemic, methods to detect the prevalence of recent and past infections are key 46 to determine public health and social countermeasures. Nucleic acid amplification tests (NAAT) 47 provide an accurate estimation of acute infections (1, 2), but they fail to inform about past infections. 48 Serological tests that detect antibodies directed against structural targets of the virus, not only are useful to estimate the overall viral seroprevalence and rates of infection in the population (3-5), but 49 50 also help to assess responses to vaccination (6), to determine correlates of protection (7, 8), and to 51 test and standardize therapeutic approaches such as monoclonal antibody and plasma transfer 52 therapies (9). Moreover, estimation of viral seroprevalence and quantification of antibody levels 53 adds to our understanding of the immune response and protection at the individual and population 54 levels (10).

55

56 Currently, serological assays to detect antibodies against SARS-CoV-2 are based on recombinant versions of the spike (S), the receptor binding domain (RBD) of S, or the nucleoprotein (NP) as 57 58 substrate (11). A variety of research grade and commercial S-based and NP-based assays are now 59 available, but antibodies to these two targets have different characteristics. Antibodies directed against the viral spike are retained for several months after infection (12-17) and correlate with 60 virus neutralization and protection against re-infection (6, 13, 18-21). Moreover, vaccination relies 61 62 uniquely on the viral spike, evidencing the importance of detecting antibodies against this target 63 with high levels of sensitivity and specificity (6).

64

Several studies evaluate the sensitivity and specificity of individual assays, either S- or NP- based, 65 however longitudinal side-by-side comparisons of different serological platforms are scarce. Here, 66 67 we employed samples from a high-risk cohort of health care workers (HCWs) using three different 68 serological assays. In addition, SARS-CoV-2 post-vaccination samples were included in the analysis. 69 We compared a research grade RBD and spike based tandem enzyme-linked immunosorbent assay 70 (ELISA) developed at Mount Sinai (MS ELISA, research grad version), the Seroklir commercial RBD-71 spike based ELISA from Kantaro Biosciences, and the commercial NP-based chemiluminescent 72 microparticle immunoassay (CMIA) Abbott Architect.

73

74 Methods

75 Research grade ELISAs

76 Detection of receptor binding domain (RBD) and full-length spike (S) antibodies in plasma was 77 performed with a research-grade two-step ELISA developed at Mount Sinai closely resembling an 78 assay used in Mount Sinai's CLIA-certified Clinical Pathology Laboratory, which received FDA 79 Emergency Use Authorization in April 2020 (22, 23). The research grade assay has 95% sensitivity 80 and 100% specificity (3). Before performing the ELISA, samples were heat-inactivated for 1h at 56°C. Briefly, for RBD screening, 96-well plates (Thermo Fisher) were coated with 50ul/well of 81 82 phosphate-buffered saline (PBS; Gibco) containing 2µg/ml of recombinant RBD protein and 83 incubated overnight at 4 °C. Plates were washed three times with PBS containing 0.1% Tween-20 84 (PBS-T; Fisher Scientific) using an automated plate washer (BioTek). For blocking, 200ul/well of 85 PBS-T containing 3% (w/v) of milk powder (American Bio) were added and plates were incubated for 1 h at room temperature. Plasma samples were diluted (1:50) in PBS-T containing 1% milk 86 87 powder. Blocking solution was removed and dilutions of samples were added. After a 2-hour 88 incubation, plates were washed three times with PBS-T and 50µl/well of anti-human IgG (Fab-89 specific) horseradish peroxidase antibody (Sigma, A0293) diluted 1:3,000 in PBS-T 1% milk powder 90 were added. Plates were incubated for 1 h at room temperature, followed by three times washing 91 with PBS-T and addition of developing solution (100µl/well) sigmafast o-phenylenediamine 92 dihydrochloride (Sigma). The reaction was led to proceed for 10 min, and stopped using 50µl/well 93 of 3-molar hydrochloric acid (Thermo Fisher). Optical density was measured at 490 nm using an 94 automated plate reader (BioTek). Samples with an OD_{490nm} above 0.15 (cut-off value) were 95 considered as presumptive positives and were further tested in the confirmatory ELISA using the 96 full-length recombinant spike protein.

97

Briefly, to perform the confirmatory ELISAs, plates were coated and blocked as described above, but using full-length spike protein for coating. Presumptive positive plasma samples were serially diluted (1:3) in 1%-milk prepared in PBS-T, starting at an initial dilution of 1:80. Serial dilutions (100µl/well) were added to the plates, followed by 2-hour incubation at room temperature. The remaining steps were performed as described above. Data was analyzed using GraphPad Prism 7. Samples with an OD_{490nm} above 0.15 (cut-off value) at a 1:80 plasma dilution were considered

positive. Samples with an OD_{490nm} above 0.15 at the last dilution were further diluted (1:2160
initially) and re-tested. Only samples positive in both steps of the assay were considered positive.

106

107 Kantaro ELISAs

108 ELISAs to detect antibodies in plasma against the receptor binding domain (RBD) and the full-length 109 spike (S) based on the commercial Kantaro Quantitative SARS-CoV-2 IgG Antibody Kit (COVID-110 SeroKlir, Kantaro Biosciences) were used. The assay was performed according to manufacturer's 111 instructions except for additional serum dilution steps in highly reactive individuals. All reagents 112 and microplates were included with the commercial kit. Briefly, for qualitative RBD ELISAs, samples were diluted in sample buffer (1:100) using 96-well microtitre plates, and 100ul/well of pre-diluted 113 114 samples were transferred to the RBD pre-coated microplates. Positive and negative controls were 115 added to every plate. Samples were incubated for 2 hours at room temperature, followed by 116 removal of plasma dilutions and washing three times with wash buffer. RBD conjugate was diluted 117 in conjugate buffer and 100µl/well were added to the plates. After 1h incubation, conjugate was 118 removed and plates were washed three times with wash buffer. Substrate solution was added 119 (100µl/well) and after 20min incubation, 100µl/well of stop solution were added. Samples were 120 read at OD_{450nm} and at OD_{570nm} for wavelength correction. The cutoff index (CI) was calculated by 121 dividing the corrected OD of the clinical sample/corrected OD of RBD positive control. Samples with 122 a CI above 0.7 were considered as presumptive positives and were further tested in the 123 confirmatory quantitative ELISA based on the full-length recombinant spike protein.

124

125 For quantitative spike ELISAs, presumptive positive plasma samples were diluted (1:200) in sample 126 buffer. Dilutions were added in duplicate to the pre-coated microplates. Low, medium and high 127 controls, as well as spike calibrators used to generate a standard curve, were added to every 128 microplates. After 2h incubation at room temperature, the remaining steps were performed as 129 described above. Data was analyzed using GraphPad Prism 7. Concentration of spike-reactive 130 antibodies was calculated using a four parameter logistic (4-PL) curve fit. Samples exceeding the 131 range of the standard curve were further diluted (1:5400) and re-tested. Only samples positive in 132 both steps of the assay were considered positive.

133

134 Abbott Architect CMIA

135 The Architect test (Abbott Laboratories) consists of an automated, two-step, qualitative CMIA for 136 qualitatively detecting IgG against the nucleoprotein (N) antigen from SARS-CoV-2. This test has a reported sensitivity of 100% (CI 95.8–100%) and specificity of 99.6 (CI 99–99.9%) 14 days after 137 138 symptom onset. The assay was performed according to manufacturer's instructions. All reagents 139 were included with the kit. Briefly, sample, SARS-CoV-2 antigen coated paramagnetic 140 microparticles, and assay diluent were combined and incubated. The IgG antibodies to SARS-CoV-2 141 present in the sample bind to the SARS-CoV-2 antigen coated microparticles. The mixture is washed. 142 Anti-human IgG acridinium-labeled conjugate is added to create a reaction mixture and incubated. 143 Following a wash cycle, Pre-Trigger and Trigger Solutions are added. The resulting 144 chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the 145 146 system optics. This relationship is reflected in the calculated Index (S/C). The presence or absence 147 of IgG antibodies to SARS-CoV-2 in the sample is determined by comparing the chemiluminescent 148 RLU in the reaction to the calibrator RLU.

149

150 Study participants and human samples

The samples used for the longitudinal study, were part of a cross sectional cohort of healthcare workers (HCWs) of the New York City Public Hospital in the South Bronx. This study was approved by the Institutional Review Board (IRB#20-009). Samples were collected in two phases: Phase 1 samples were obtained in May 2020 and Phase 2 samples were collected from August to October 2020. Informed consent was obtained prior to Phase 1 sample collection.

Samples from study participants receiving the Pfizer mRNA vaccine were obtained from IRB approved longitudinal observation studies (IRB-16-00791; IRB-20-03374) conducted by the Personalized Virology Initiative (PVI) at the Icahn School of Medicine at Mount Sinai. All participants signed informed consents prior to data and sample collection. All serum samples were coded upon collection and analyzed in a blinded manner in the Krammer laboratory.

161

162 Statistical analysis

163 Correlations of antibody levels in the different assays were calculated using a standard Pearson's 164 correlation. Coefficients of correlation (r) are presented. Paired t-test for comparison of phase 1 and 165 phase 2 antibody levels was used. All adjusted P values of <0.05 were considered statistically

significant with a confidence interval of 95%. Statistical analyses were performed using Prism 7(GraphPad, USA).

- 168
- 169 **Results**

Longitudinal comparison of SARS-CoV-2 seroprevalence using RBD/spike and NP based assays

Seroprevalence of SARS-CoV-2 across different regions of the world has been described using 172 173 multiple serological assays based either on the spike protein (S), its receptor-binding domain (RBD), 174 or the nucleoprotein (NP). Here we compared side-by-side a research grade MS ELISA based on RBD 175 and spike, an RBD/spike based SeroKlir assay from Kantaro Biosciences and the NP based Abbott 176 Architect test. We used a set of 501 samples from frontline healthcare workers (HCW) collected after the first pandemic wave in the New York City area (May 2020). Seroprevalence in this set of 177 samples using a research grade ELISA from Mount Sinai was 28.4%, (142/501), 28.1%, using the 178 179 SeroKlir test from Kantaro Biosciences (141/501) and 27.3% using the Abbott Architect test 180 (137/501) (**Fig. 1A**). A subset of the initial participants (n=178) attended provided a second serum sample at a follow up visit in August-October 2020 allowing assessment of seroprevalence at two 181 182 different time points. Of note, the seroprevalence in the smaller subset of participants was higher 183 compared to the initial cohort (N=501). This is likely due to higher compliance of participants that 184 knew their sero-status in the first phase, since they were informed about their antibody levels. 185 Overall, the seroprevalence measured by the Mount Sinai and the Kantaro ELISAs did not vary 186 significantly between the two time points (Fig. 1B-1C), but the seroprevalence of NP reactive 187 antibodies measured by the Abbott Architect test declined (Fig. 1D).

188

189 We further compared the antibody levels in samples obtained during the first phase (May 2020) 190 and the second phase (Aug-Oct, 2020) in the subset of 178 subjects (the distribution of antibody 191 levels is shown in **Sup. Fig. 1** and concordance analyses among the different assays are shown in 192 **Sup. Fig. 2**). As expected, antibody levels in the second phase declined in the majority of participants 193 in a manner that was consistent in the three different assays (Figs. 2A-2C). A sharper decline of NP 194 reactive antibody levels as measured by the Abbott Architect test (Fig. 2C). Moreover, the 195 percentage of subjects that were seropositive initially and whose antibodies became undetectable 196 in the second phase did not vary significantly in the Mount Sinai and Kantaro ELISAs (Figs. 2A-2B)

but 30% of the samples that were positive initially in the Abbott Architect test became negative in
the second phase (Fig. 2B).

199

200 **Correlation of antibody levels among the different assays**

The antibody response against different antigenic targets of a particular virus exhibits a high degree 201 202 of complexity. The magnitude and kinetics of the antibody response against RBD/spike and the 203 nucleoprotein are not fully understood. To analyze the consistency between the two RBD/spike 204 based assays and to study the relationship of RBD/spike reactive antibodies versus NP reactive 205 antibodies, we performed correlation analyses among the three different assays. Using the positive 206 samples from the first (Figs. 3A-C) and second (Figs. 3D-2F) phases, we detected a good correlation 207 of RBD reactive antibodies (optical density (OD) measured at one dilution) measured by the Mount 208 Sinai ELISA versus the Kantaro ELISA either in phase 1 (r= 0.9169; P two-tailed= <0.0001, Fig. 3A) 209 or phase 2 (r= 0.9075; P two-tailed= <0.0001, Fig. 3D). However, the correlation of RBD reactive 210 antibodies measured in the Mount Sinai or Kantaro assays versus the NP reactive antibodies 211 measured in the Abbott Architect test, either in phase 1 (Figs. 3B-3C) or phase 2 (Figs. 3E-3F) 212 samples, was modest to low.

213 We performed next the same type of analyses but with quantitative spike reactive antibody levels instead of RBD reactive antibody OD values. Again, we found a good correlation between the Mount 214 215 Sinai ELISA vs the Kantaro ELISA either in phase 1 (r= 0.6860; P two-tailed= <0.0001, Fig. 4A) or 216 phase 2 (r= 0.9135: P two-tailed = <0.0001. Fig. 4D) and a weak correlation between spike reactive 217 antibodies measured in the Mount Sinai or Kantaro assays versus the NP reactive antibodies 218 measured in the Abbott Architect test (Figs. 4B-4C: phase 1; Figs. 4E-4F: phase 2). For both RBD 219 and spike, some of the subjects exhibited very high levels of RBD reactive antibodies and low levels 220 of NP reactive antibodies and vice versa. Overall, these findings indicate that the magnitude of 221 RBD/spike and NP antibody responses differs considerably highlighting the need for further studies 222 using samples from well-described longitudinal cohort studies.

- 223
- 224 225
- 226 Detection of vaccine induced antibodies in both assays

227 To date only limited data is available about how commercial antibody assays respond to antibodies 228 developed in response to vaccination. In order to determine how the three assays perform against 229 vaccine-induced antibodies, we measured reactivity in serum of individuals who had received two 230 doses of SARS-CoV-2 mRNA vaccines. The expectation was, that the RBD/spike based assays would 231 detect a signal while the NP based assay would not. Indeed, we measured high titers using the Spike 232 based assay platforms (the Mount Sinai and Kantaro assays) but the samples produced no signal in 233 the NP-based assay (Fig. 5A-5C). Of note, the spike titers measured in the Mount Sinai and Kantaro 234 assay correlated very well (Fig. 5D).

235

236 **Discussion**

237 While antibody responses to acute SARS-CoV-2 infection are relatively well understood, less data is 238 available regarding antibody kinetics over longer time frames against different viral antigens. We 239 determined seroprevalence and antibody titers in SARS-CoV-2 infected individuals at two time 240 points (1-2 months and 3-4 months post infection) using three different assays. One assay, the 241 Mount Sinai ELISA, is a laboratory-developed assay that uses an initial ELISA at a single serum 242 dilution against the RBD followed by a confirmation and titration against the full-length spike 243 protein. The second assay tested, the Kantaro SeroKlir assay, is based on the same principle, but 244 commercially available. The third assay, the Abbott Architect, targets the NP and is a CMIA.

245 There was high concordance among the three assays with respect to seroprevalence during phase 246 1. However, the titers only correlated well for the two spike-based assays. During phase 2, the two 247 spike-based assays identified all (Mount Sinai Research grade) or the vast majority (Kantaro) of 248 previously seropositive individuals as seropositive, while the NP based assay (Abbott) failed to 249 detect a signal above the cut-off in approximately 30% of previously positive individuals. These 250 findings mirror similar results recently published by Grandjean and colleagues, suggesting that the 251 NP antibody response is short-lived (24). However, it could also be a reflection of a high cut-off 252 required to ensure high specificity for SARS-CoV-2 in the NP-based assay. Importantly, and as 253 expected since no NP is included in the FDA EUA approved vaccines used in the US, only the spike-254 based assays were able to detect antibodies induced by SARS-CoV-2 mRNA vaccines (6). Our data 255 highlight the need to understand assay performance before a specific assay is used to study specific 256 aspects of SARS-CoV-2 immunity. All three assays are very valuable to assess seroconversion 257 shortly after infection, but only the two spike-based assays were reliable months after recovery.

258 Similarly, only spike-based assays are fit for measuring vaccine-induced antibodies, e.g. to 259 determine if vaccination triggered immune responses.

260

261 Acknowledgements

262 We thank the study participants for their continued generosity and willingness to support our 263 longitudinal studies and our colleagues Adolfo Firpo and Carlos Cordon-Cardo for supporting our 264 collaborative serology work. We also acknowledge the continued efforts of the Personalized 265 Virology Initiative (in alphabetical order: Bulbul Ahmed, Hala Alshammary, Angela Amoako, 266 Mahmoud Awawda, Katherine Beach, Carolina Bermúdez-González, Rachel Chernet, Lily Eaker, 267 Shelcie Fabre, Emily. D. Ferreri, Daniel Floda, Charles Gleason, Dr. Giulio Kleiner, Dr. Denise 268 Jurczyszak, Julia Matthews, Wanni Mendez, Dr. Lubbertus CF Mulder, Jose Polanco, Kayla Russo, 269 Ashley Salimbangon, Dr. Miti Saksena, A. Shin, Levy Sominsky, Komal Srivastava, Sayahi 270 Suthakaran). We thank research associates for their assistance with sample processing at Lincoln 271 Hospital: Dominika Bielak, Ajmal Khan and Syed Hamad Ali Shah. Work in the Krammer and the 272 Simon laboratories is partially funded by the NIAID Collaborative Influenza Vaccine Innovation 273 Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and 274 Surveillance (CEIRS, contract # HHSN272201400008C), by the generous support of the JPB 275 Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by 276 anonymous donors. This effort was also supported by the Serological Sciences Network (SeroNet) 277 in part with Federal funds from the National Cancer Institute. National Institutes of Health, under 278 Contract No. 75N91019D00024. Task Order No. 75N91020F00003. The content of this publication 279 does not necessarily reflect the views or policies of the Department of Health and Human Services, 280 nor does mention of trade names, commercial products or organizations imply endorsement by the 281 U.S. Government.

282

283 **Conflict of interest statement**

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2
serological assays (the "Serology Assays") and NDV-based SARS-CoV-2 vaccines which list
Florian Krammer (the "Serology Assays", vaccines) and Viviana Simon ("Serology Assays") as coinventors. The foundational "Serology Assay" intellectual property (IP) was licensed by the Icahn
School of Medicine at Mount Sinai to commercial entities including Kantaro Biosciences, a

- 289 company in which Mount Sinai has a financial interest. Kantaro manufactures and markets
- serologic tests based on the Mount Sinai IP. It is anticipated that the medical school will receive
- 291 payments related to commercialization of the "Serology Assay" IP and, as faculty inventors, Drs.
- 292 Krammer and Simon will be entitled to a portion of these payments.
- 293 Florian Krammer consulted for Merck, Curevac and Pfizer in the past (before 2020) and is
- 294 currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is collaborating with
- 295 Pfizer on animal models of SARS-CoV-2.
- 296
- 297 **References**:
- 298
- Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. 2020. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 20:411-412.
- Chu DKW, Pan Y, Cheng SMS, Hui KPY, Krishnan P, Liu Y, Ng DYM, Wan CKC, Yang P, Wang Q,
 Peiris M, Poon LLM. 2020. Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing
 an Outbreak of Pneumonia. Clin Chem 66:549-555.
- Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA,
 McMahon M, Capuano C, Twyman K, Jhang J, Nowak MD, Simon V, Sordillo EM, van Bakel H,
 Krammer F. 2020. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York
 City. Nature.
- Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S,
 Mokdad AH, Hotez PJ, Gasser RB. 2020. SARS-CoV-2 seroprevalence worldwide: a systematic
 review and meta-analysis. Clin Microbiol Infect.
- Angulo FJ, Finelli L, Swerdlow DL. 2021. Estimation of US SARS-CoV-2 Infections,
 Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. JAMA
 Netw Open 4:e2033706.
- 314 6. Krammer F. 2020. SARS-CoV-2 vaccines in development. Nature 586:516-527.
- McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo
 C, Zhu A, Bondzie EA, Dagotto G, Gebre MS, Jacob-Dolan C, Li Z, Nampanya F, Patel S, Pessaint
 L, Van Ry A, Blade K, Yalley-Ogunro J, Cabus M, Brown R, Cook A, Teow E, Andersen H, Lewis
 MG, Lauffenburger DA, Alter G, Barouch DH. 2020. Correlates of protection against SARS CoV-2 in rhesus macaques. Nature.
- Brown M. 2020. Immune correlates of SARS-CoV-2 protection. Nat Rev Immunol 20:593.
- Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, Huang
 J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, Hu Y, Lin
 L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng
 X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X. 2020.
 Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad
 Sci U S A 117:9490-9496.
- 327 10. Cohen MS. 2021. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
 328 N Engl J Med 384:289-291.
- 11. Krammer F, Simon V. 2020. Serology assays to manage COVID-19. Science 368:1060-1061.

- 12. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier
 A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM,
 Weiskopf D, Sette A, Crotty S. 2020. Immunological memory to SARS-CoV-2 assessed for up
 to eight months after infection. bioRxiv.
- Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P,
 Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S, Simon V, Aberg J, Reich DL,
 Krammer F, Cordon-Cardo C. 2020. Robust neutralizing antibodies to SARS-CoV-2 infection
 persist for months. Science 370:1227-1230.
- Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, Li Z, Chao G, Rojas OL, Bang YM, Pu A, Christie-Holmes N, Gervais C, Ceccarelli D, Samavarchi-Tehrani P, Guvenc F, Budylowski P, Li A, Paterson A, Yue FY, Marin LM, Caldwell L, Wrana JL, Colwill K, Sicheri F, Mubareka S, Gray-Owen SD, Drews SJ, Siqueira WL, Barrios-Rodiles M, Ostrowski M, Rini JM, Durocher Y, McGeer AJ, Gommerman JL, Gingras AC. 2020. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci Immunol 5.
- Iyer AS, Jones FK, Nodoushania A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oiver E, Fischinger S, Atyeo C, Iafrate AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Cardonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, Charles RC. 2020. Dynamics and significance of the antibody response to SARS-CoV-2 infection. medRxiv:2020.07.18.20155374.
- Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y,
 Huang J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered
 patient cohort and their implications. medRxiv:2020.03.30.20047365.
- 353 17. Seow J. Graham C. Merrick B. Acors S. Pickering S. Steel KJA. Hemmings O. O'Byrne A. 354 Kouphou N, Galao RP, Betancor G, Wilson HD, Signell AW, Winstone H, Kerridge C, Huettner 355 I, Jimenez-Guardeño JM, Lista MJ, Temperton N, Snell LB, Bisnauthsing K, Moore A, Green A, 356 Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, Tan MKI, O'Connell L, O'Hara G, MacMahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, 357 358 Edgeworth JD, Neil SJD, Malim MH, Doores KJ. 2020. Longitudinal observation and decline of 359 neutralizing antibody responses in the three months following SARS-CoV-2 infection in 360 humans. Nat Microbiol 5:1598-1607.
- Beng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H,
 Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C.
 2020. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.
 Science 369:818-823.
- 365 19. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J, 366 Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez DR, Atveo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook 367 368 A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, Mahrokhian SH, 369 370 Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK, 371 Estes ID, et al. 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. 372 Science 369:812-817.
- Hall V, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, Wellington E, Cole MJ, Saei A,
 Oguti B, Munro K, Wallace S, Kirwan PD, Shrotri M, Vusirikala A, Rokadiya S, Kall M, Zambon
 M, Ramsay M, Brooks T, Brown CS, Chand MA, Hopkins S. 2021. Do antibody positive

- healthcare workers have lower SARS-CoV-2 infection rates than antibody negative
 healthcare workers? Large multi-centre prospective cohort study (the SIREN study),
 England: June to November 2020. medRxiv:2021.01.13.21249642.
- Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox
 S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Cornall RJ, Jones EY,
 Stuart DI, Screaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O'Donnell AM, Conlon CP,
 Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Jeffery K, Eyre DW, Group OUHST.
 2020. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl
 J Med.
- Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, Jiang K,
 Arunkumar GA, Jurczyszak D, Polanco J, Bermudez-Gonzalez M, Kleiner G, Aydillo T, Miorin
 L, Fierer DS, Lugo LA, Kojic EM, Stoever J, Liu STH, Cunningham-Rundles C, Felgner PL, Moran
 T, García-Sastre A, Caplivski D, Cheng AC, Kedzierska K, Vapalahti O, Hepojoki JM, Simon V,
 Krammer F. 2020. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat
 Med.
- Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, Tan J, Bhavsar
 D, Capuano C, Kirkpatrick E, Meade P, Brito RN, Teo C, McMahon M, Simon V, Krammer F.
 2020. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay,
 Antigen Production, and Test Setup. Curr Protoc Microbiol 57:e100.
- Grandjean L, Saso A, Torres A, Lam T, Hatcher J, Thistlethwayte R, Harris M, Best T, Johnson M, Wagstaffe H, Ralph E, Mai A, Colijn C, Breuer J, Buckland M, Gilmour K, Goldblatt D. 2020.
 Humoral Response Dynamics Following Infection with SARS-CoV-2.
 medRxiv:2020.07.16.20155663.
- 399 400
- 401 **Figure legends**

402 Figure 1. Seroprevalence against SARS-CoV-2 in healthcare workers using different serology

platforms. Serum samples from frontline healthcare workers were assessed for antibodies against
RBD-Spike using a research grade ELISA from Mount Sinai, against RBD-Spike using a commercial
ELISA from Kantaro Biosciences, or against NP using Abbott-Architect CMIA. Initially, samples
analyzed in the three assays consisted of specimens obtained early during the pandemic on May
2020 (n=501) (A). Seroprevalence in a subset of subjects (n=178) who attended a follow up visit on
August-October 2020 was determined using the three different serological assays and a comparison
of the two time points is shown (B-C).

410

411 Figure 2. Longitudinal analysis of antibody levels against RBD-Spike or NP in seropositive

412 **subjects.** Serum samples from frontline healthcare workers were obtained on May 2020 or August-

413 October 2020. Antibodies against RBD-Spike were measured using a research grade ELISA from

Mount Sinai (A); against RBD-Spike using a commercial ELISA from Kantaro Biosciences (B); or
against NP using the Abbott-Architect CMIA (C). Antibody levels in specimens obtained early during
the pandemic on May 2020 or in a follow up visit on August-October 2020 are shown. Samples with
a value above or below the cutoff of the corresponding assay (doted line) are shown. **** P<0.0001.
The percentage of seropositive samples that turned negative (red) or that remained positive (blue)

- 419 as measured in each of the corresponding assays is shown in **D-F**.
- 420

421 Figure 3. Correlation analysis of antibody levels (RBD-reactive) among the different serology 422 assays. Serum samples were assessed for antibodies against RBD-Spike using a research grade 423 ELISA from Mount Sinai, against RBD-Spike using a commercial ELISA from Kantaro Biosciences or 424 against NP using the Abbott-Architect CMIA. Correlation of antibody levels (RBD reactive) among 425 the different assays using serum samples obtained on May 2020 (first time point) is shown (A-C). 426 Correlation of antibody levels (RBD reactive) among the different assays using serum samples 427 obtained on August-October 2020 (second time point) is shown (**D-F**). Correlation analysis between 428 Mount Sinai RBD and Kantaro RBD ELISAs (A, D): between Mount Sinai RBD and Abbott Architect 429 NP ELISAs (B, E); and between Kantaro RBD ELISAs and Abbott Architect NP CMIAs (C, F) are 430 shown. Pearson correlation was used. Significance and coefficient of determination are shown.

431

432 Figure 4. Correlation analysis of antibody levels (spike-reactive) among the different 433 **serology assays.** Serum samples were assessed for antibodies against RBD-Spike using a research 434 grade ELISA from Mount Sinai, against RBD-Spike using a commercial ELISA from Kantaro 435 Biosciences or against NP using the Abbott-Architect CMIA. Correlation of antibody levels (spike 436 reactive) among the different assays using serum samples obtained on May 2020 (first time point) 437 is shown (A-C). Correlation of antibody levels (spike reactive) among the different assays using 438 serum samples obtained on August-October 2020 (second time point) is shown (**D-F**). Correlation 439 analysis between Mount Sinai RBD and Kantaro RBD ELISAs (A, D); between Mount Sinai RBD and 440 Abbott Architect NP CMIAs (**B**, **E**); and between Kantaro RBD ELISAs and Abbott Architect NP CMIAs 441 (C, F) are shown. Pearson correlation was used. Significance and coefficient of determination are shown. 442

444 Figure 5. Post SARS-CoV-2 mRNA vaccination serum titers as measured in three different

assays. Serum samples of individuals who had received two doses of SARS-CoV-2 mRNA vaccines
were assessed for antibodies against RBD-spike using a research grade ELISA from Mount Sinai (A),
against RBD-spike using a commercial ELISA from Kantaro Biosciences (B) or against NP using the
Abbott-Architect CMIA (C). Correlation of antibody levels (spike reactive) between the Mount Sinai
ELISA and the commercial ELISA from Kantaro Biosciences assays using the same serum samples
(D).

451

Supplementary Figure 1. Distribution of antibody levels (spike-reactive) in the different serology platforms. Serum samples were assessed for antibodies against RBD-Spike using a research grade ELISA from Mount Sinai (A, D), against RBD-Spike using a commercial ELISA from Kantaro Biosciences (B, E), or against NP using the Abbott-Architect ELISA (C, F). Distribution of antibody levels (spike-reactive) early during the pandemic on May 2020 (A-C) or in August-October 2020 (D-E) are shown.

458

459 Supplementary Figure 2. Concordance analysis of positive samples among the different 460 serology assays. Venn diagrams depicting the number of seropositive samples measured by a RBD-Spike research grade ELISA from Mount Sinai (blue); a RBD-Spike commercial ELISA from Kantaro 461 462 Biosciences (red), or an Abbott-Architect NP ELISA (green). Concordance of positivity among the 463 three different assays using samples obtained early during the pandemic on May 2020 is shown (\mathbf{A}). 464 Scroprevalence in a subset of subjects (n=178) who attended a follow up visit on August-October 465 2020 was determined using the three different serological assays. Concordance of positivity in that 466 subset of subjects on May 2020 (**B**) or August-October 2020 (**C**) is shown.











Supplementary figure 1



